bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
All Web sites
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: S A J J M A M F J
2013: D N O S

  Health Highlights: July 17, 2014

Here are some of the latest health and medical news developments, compiled by the editors of HealthDay:

New Hepatitis C Drug a $55 Billion Burden for States: Study

It could cost state Medicaid programs more than $55 billion to pay for a breakthrough drug to treat hepatitis C, according to a study by pharmacy benefits firm Express Scripts.

The drug, Sovaldi, costs $1,000 a day for a 12-week treatment, even with a 23 percent Medicaid plan discount, CNBC reported.

Nationwide, more than 750,000 Medicaid patients and prisoners covered by state health programs have chronic hepatitis C, which can lead to liver cancer. States facing the largest bills for hepatitis C spending include California ($6.7 billion), Texas ($5.3 billion), and Florida and New York (nearly $4 billion each), according to Express Scripts.

The cost of treating hepatitis C is a huge burden for state health systems, Dr. Steve Miller, Express Scripts medical director, told CNBC.

"These states are saying 'What is it we're supposed to do?'" Miller said. "This is just unimaginable for state budgets today."

------

New Drug Approved for Rare Disease That Causes Sudden Swelling

A new drug to treat a rare but potentially life-threatening genetic disease called hereditary angioedema (HAE) has been approved by the U.S. Food and Drug Administration.

HAE, which affects 6,000 to 10,000 people in the U.S., is caused by insufficient amounts of a plasma protein called C1-esterase inhibitor. People with the disease can develop sudden swelling of the hands, feet, limbs, face, intestinal tract, or airway.

These attacks of swelling can occur on their own or be triggered by stress, infection or surgery. Without immediate treatment, swelling of the airway can be deadly.

The newly-approved drug for HAE is called Ruconest. It is designed to restore the normal level of C1-esterase inhibitor in a patient's plasma in order to treat sudden attacks of swelling, the FDA said.

The approval is based on a study of 44 adults and teens with HAE whose swelling attacks were treated with Ruconest. Common side effects caused by the drug included headache, nausea and diarrhea.

The drug is made by Pharming Group NV of the Netherlands and will be distributed in the U.S. by Santarus Inc., a subsidiary of Salix Pharmaceuticals Inc.

------

CDC Lacks 'Culture of Safety': Director

Recent safety lapses at the U.S. Centers for Disease Control and Prevention -- such as the mishandling of live anthrax and accidental contamination of specimens with a dangerous bird flu strain -- show that the agency lacks a "culture of safety," CDC Director Tom Frieden said Wednesday.

Meanwhile, the U.S. Food and Drug Administration delivered disturbing news of its own as Frieden concluded his testimony before Congress on the CDC incidents.

In addition to finding six forgotten vials of smallpox virus recently, more than 300 other sealed vials containing biological materials such as dengue, influenza, Q fever, ricksettsia and other possible unknown viruses were found in the same cold storage room on the U.S. National Institutes of Health campus.

A sweep of all cold storage facilities has been ordered, USA Today reported.

FDA officials noted that the other pathogens listed on the additional vials do not pose the same threat as smallpox, the newspaper said.

In his testimony, CDC Director Frieden said the anthrax incident at his agency "was completely unacceptable. It should never have happened," USA Today reported.

"With the recent incidents, we recognize a pattern at CDC where we need to greatly improve the culture of safety," Frieden told an oversight committee of the House Comittee on Energy and Commerce. "What we're seeing is a pattern that we missed, and the pattern is an insufficient culture of safety."

Frieden said he is personally in charge of efforts to improve safety, such as closing two labs involved in two recent high-profile errors, the appointment of a senior scientist to be the single official in charge of lab safety, and suspending the transfer of biologic specimens from all the CDC's biosafety level 3 and 4 labs, USA Today reported.

However, U.S. Rep. Fred Upton, R-Mich., noted that many of the measures sound like remedies the CDC said it made two years ago after the committee investigated safety issues at a CDC lab complex.

"Why should we believe this time things will be different?" Upton asked, USA Today reported.

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=689859

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Hepatitis C
Hepatitis
Plasma
Therapeutics
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact